欧洲委员会罚款Teva制药公司5 000万美元,罪名是滥用科帕松专利。 European Commission fines Teva Pharmaceutical $500m for patent misuse regarding Copaxone.
欧盟委员会对Teva制药工业公司罚款5亿美元,原因是滥用专利制度扩大对其多种硬化药物Copaxone的保护。 The European Commission has fined Teva Pharmaceutical Industries $500 million for misusing the patent system to extend protections for its multiple sclerosis drug, Copaxone. Teva 被指控通过传播可能阻碍竞争并阻止成本节约的错误信息来诋毁竞争对手 Synthon，后者是欧洲唯一一家拥有类似药物的公司。 Teva is accused of disparaging rival Synthon, the only other company with a similar drug in Europe, by spreading misinformation that could have hindered competition and prevented cost savings. Teva计划对该决定提出上诉,声称它不同意委员会的索赔要求。 Teva plans to appeal the decision, asserting it disagrees with the Commission's claims.